Application
GW1929 has been used as a peroxisome proliferator-activated receptor γ (PPARγ) ligand:
- to study its effects on plant homeodomain finger protein 16 (Phf16) and patatin-like phospholipase domain containing 3 (Pnpla3) expression involved in adipogenesis
- to study its effects on complement component 3 (C3) gene expression in human hepatoma cells
- to activate PPARγ in human breast cancer cells
Biochem/physiol Actions
GW1929 is a non-thiazolidinedione and is involved in cell growth inhibition and regulating gene expression. It exhibits neuroprotective effects against global cerebral ischemic-reperfusion injury by DNA fragmentation and minimizing the inflammation. GW1929 participates in the inhibition of α7 N-acetylcholine receptor expression and promoter activity. It also influences the early growth response-1 (Egr-1) protein expression.
GW1929 is a high affinity agonist of PPAR-γ.
Features and Benefits
This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes only, pursuant to an agreement with GlaxoSmithKline
- UPC:
- 41141515
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- G5668-5MG
